Metabolic Protocol - Tirzepatide

This variant of the Metabolic Protocol uses Tirzepatide as the primary appetite-regulating compound, offering dual GIP/GLP-1 receptor activation for stronger metabolic effects than semaglutide alone. Combined with MOTS-c for mitochondrial optimisation and BPC-157 for gut protection and tissue repair, it provides a comprehensive metabolic intervention.

Ideal for researchers who want the enhanced efficacy of a dual-agonist GLP-1 compound while maintaining the multi-system approach of the Metabolic Protocol.